Hereditary cancer syndrome diagnosis: Molecular genetic clues and cancer control

Henry T. Lynch, Ramon M. Fusaro, Jane F. Lynch

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Oncologists who are aware of the progress in hereditary cancer syndrome diagnosis, and, in particular, of how this effort may be effectively facilitated through a comprehensive family history in concert with molecular genetic studies, are in the envious position of designing highly targeted screening and management programs for the membership of these cancer-prone families. The Lynch syndrome is discussed as a clinical model wherein the presence of mismatch repair mutations provides a high level of diagnostic certainty for the initiation of targeted cancer screening and management. The familial atypical multiple mole melanoma-pancreatic cancer (FAMMM-PC) syndrome, on the other hand, provides another model with cancer-control potential. Given its phenotypic features of multiple atypical nevi, high total body mole count and cutaneous malignant melanoma, coupled with the integral association of PC in a subset of FAMMM kindreds with the CDKN2A germline mutation, this may result in a perhaps lower level of diagnostic certainty when compared with the Lynch syndrome. This knowledge may impact upon progress in the earlier diagnosis of melanoma and provide an impetus for creative diagnostic methods in PC, a disease that, at this time, demonstrates a mortality rate virtually identical to its incidence rate.

Original languageEnglish
Pages (from-to)169-181
Number of pages13
JournalFuture Oncology
Volume3
Issue number2
DOIs
StatePublished - Apr 2007

Fingerprint

Hereditary Neoplastic Syndromes
Hereditary Nonpolyposis Colorectal Neoplasms
Molecular Biology
Dysplastic Nevus Syndrome
DNA Mismatch Repair
Germ-Line Mutation
Nevus
Early Detection of Cancer
Early Diagnosis
Melanoma
Neoplasms
Mutation
Mortality
Incidence

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Hereditary cancer syndrome diagnosis : Molecular genetic clues and cancer control. / Lynch, Henry T.; Fusaro, Ramon M.; Lynch, Jane F.

In: Future Oncology, Vol. 3, No. 2, 04.2007, p. 169-181.

Research output: Contribution to journalArticle

Lynch, Henry T. ; Fusaro, Ramon M. ; Lynch, Jane F. / Hereditary cancer syndrome diagnosis : Molecular genetic clues and cancer control. In: Future Oncology. 2007 ; Vol. 3, No. 2. pp. 169-181.
@article{b3841f924bac477cb42321f0faf680b1,
title = "Hereditary cancer syndrome diagnosis: Molecular genetic clues and cancer control",
abstract = "Oncologists who are aware of the progress in hereditary cancer syndrome diagnosis, and, in particular, of how this effort may be effectively facilitated through a comprehensive family history in concert with molecular genetic studies, are in the envious position of designing highly targeted screening and management programs for the membership of these cancer-prone families. The Lynch syndrome is discussed as a clinical model wherein the presence of mismatch repair mutations provides a high level of diagnostic certainty for the initiation of targeted cancer screening and management. The familial atypical multiple mole melanoma-pancreatic cancer (FAMMM-PC) syndrome, on the other hand, provides another model with cancer-control potential. Given its phenotypic features of multiple atypical nevi, high total body mole count and cutaneous malignant melanoma, coupled with the integral association of PC in a subset of FAMMM kindreds with the CDKN2A germline mutation, this may result in a perhaps lower level of diagnostic certainty when compared with the Lynch syndrome. This knowledge may impact upon progress in the earlier diagnosis of melanoma and provide an impetus for creative diagnostic methods in PC, a disease that, at this time, demonstrates a mortality rate virtually identical to its incidence rate.",
author = "Lynch, {Henry T.} and Fusaro, {Ramon M.} and Lynch, {Jane F.}",
year = "2007",
month = "4",
doi = "10.2217/14796694.3.2.169",
language = "English",
volume = "3",
pages = "169--181",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Hereditary cancer syndrome diagnosis

T2 - Molecular genetic clues and cancer control

AU - Lynch, Henry T.

AU - Fusaro, Ramon M.

AU - Lynch, Jane F.

PY - 2007/4

Y1 - 2007/4

N2 - Oncologists who are aware of the progress in hereditary cancer syndrome diagnosis, and, in particular, of how this effort may be effectively facilitated through a comprehensive family history in concert with molecular genetic studies, are in the envious position of designing highly targeted screening and management programs for the membership of these cancer-prone families. The Lynch syndrome is discussed as a clinical model wherein the presence of mismatch repair mutations provides a high level of diagnostic certainty for the initiation of targeted cancer screening and management. The familial atypical multiple mole melanoma-pancreatic cancer (FAMMM-PC) syndrome, on the other hand, provides another model with cancer-control potential. Given its phenotypic features of multiple atypical nevi, high total body mole count and cutaneous malignant melanoma, coupled with the integral association of PC in a subset of FAMMM kindreds with the CDKN2A germline mutation, this may result in a perhaps lower level of diagnostic certainty when compared with the Lynch syndrome. This knowledge may impact upon progress in the earlier diagnosis of melanoma and provide an impetus for creative diagnostic methods in PC, a disease that, at this time, demonstrates a mortality rate virtually identical to its incidence rate.

AB - Oncologists who are aware of the progress in hereditary cancer syndrome diagnosis, and, in particular, of how this effort may be effectively facilitated through a comprehensive family history in concert with molecular genetic studies, are in the envious position of designing highly targeted screening and management programs for the membership of these cancer-prone families. The Lynch syndrome is discussed as a clinical model wherein the presence of mismatch repair mutations provides a high level of diagnostic certainty for the initiation of targeted cancer screening and management. The familial atypical multiple mole melanoma-pancreatic cancer (FAMMM-PC) syndrome, on the other hand, provides another model with cancer-control potential. Given its phenotypic features of multiple atypical nevi, high total body mole count and cutaneous malignant melanoma, coupled with the integral association of PC in a subset of FAMMM kindreds with the CDKN2A germline mutation, this may result in a perhaps lower level of diagnostic certainty when compared with the Lynch syndrome. This knowledge may impact upon progress in the earlier diagnosis of melanoma and provide an impetus for creative diagnostic methods in PC, a disease that, at this time, demonstrates a mortality rate virtually identical to its incidence rate.

UR - http://www.scopus.com/inward/record.url?scp=34247135358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247135358&partnerID=8YFLogxK

U2 - 10.2217/14796694.3.2.169

DO - 10.2217/14796694.3.2.169

M3 - Article

C2 - 17381417

AN - SCOPUS:34247135358

VL - 3

SP - 169

EP - 181

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 2

ER -